Fludarabine in chronic lymphocytic leukaemia

Bibliography

• REDAELLI A, LASKIN BL, STEPHENS JM, BOTTEMAN MF, PASHOS CL: The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care (Engl.) (2004) 13(3):279-287.
   Google Scholar
• JEMAL A, MURRAY T, WARD E et al.: Cancer statistics, 2005. CA Cancer J. Clin. (2005) 55(1):10-30.
   PubMed Web of Science ®Google Scholar
• BYRD JC, STILGENBAUER S, FLINN IW: Chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ. Program (2004):163-183.
   PubMedGoogle Scholar
• LAMANNA N: Advances in the treatment of chronic lymphocytic leukemia. Curr. Oncol. Rep. (2005) 7(5):333-338.
   Google Scholar
• ROBAK T, KORYCKA A, KASZNICKI M, WRZESIEN-KUS A, SMOLEWSKI P: Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr. Cancer Drug Targets (2005) 5(6):421-444.
   Google Scholar
• MONTGOMERY JA, HEWSON K: Nucleosides of 2-fluoroadenine. J. Med. Chem. (1969) 12(3):498-504.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O’BRIEN S, MCLAUGHLIN P et al.: Clinical experience with fludarabine in hemato-oncology. Hematol. Cell Ther. (1996) 38(Suppl. 2):S83-S91.
   Google Scholar
• BROCKMAN RW, CHENG YC, SCHABEL FM Jr, MONTGOMERY JA: Metabolism and chemotherapeutic activity of 9-β-d-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res. (1980) 40(10):3610-3615.
   PubMed Web of Science ®Google Scholar
• DANHAUSER L, PLUNKETT W, KEATING M, CABANILLAS F: 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother. Pharmacol. (1986) 18(2):145-152.
   PubMed Web of Science ®Google Scholar
• BARRUECO JR, JACOBSEN DM, CHANG CH, BROCKMAN RW, SIROTNAK FM: Proposed mechanism of therapeutic selectivity for 9-β-d-arabinofuranosyl-2-fluoroadenine against murine leukemia based upon lower capacities for transport and phosphorylation in proliferative intestinal epithelium compared to tumor cells. Cancer Res. (1987) 47(3):700-706.
   PubMed Web of Science ®Google Scholar
• PLUNKETT W, CHUBB S, ALEXANDER L, MONTGOMERY JA: Comparison of the toxicity and metabolism of 9-β-d-arabinofuranosyl-2-fluoroadenine and 9-β-d-arabinofuranosyladenine in human lymphoblastoid cells. Cancer Res. (1980) 40(7):2349-2355.
   PubMed Web of Science ®Google Scholar
• TSENG WC, DERSE D, CHENG YC, BROCKMAN RW, BENNETT LL Jr: In vitro biological activity of 9-β-d-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol. (1982) 21(2):474-477.
   PubMed Web of Science ®Google Scholar
• WHITE EL, SHADDIX SC, BROCKMAN RW, BENNETT LL Jr: Comparison of the actions of 9-β-d-arabinofuranosyl-2-fluoroadenine and 9-β-d-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res. (1982) 42(6):2260-2264.
   PubMed Web of Science ®Google Scholar
• GANDHI V, PLUNKETT W: Cellular and clinical pharmacology of fludarabine. Clin. Pharmacokinet. (2002) 41(2):93-103.
   PubMed Web of Science ®Google Scholar
• DIGHIERO G: Adverse and beneficial immunological effects of purine nucleoside analogues. Hematol. Cell Ther. (1996) 38(Suppl. 2):S75-S81.
   Google Scholar
• GRIBBIN TE: New purine analogues for the treatment of chronic B-cell malignancies. Henry Ford. Hosp. Med. J. (1991) 39(2):98-102.
   Google Scholar
• YAMAUCHI T, NOWAK BJ, KEATING MJ, PLUNKETT W: DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. (2001) 7(11):3580-3589.
   PubMed Web of Science ®Google Scholar
• NOKER PE, DUNCAN GF, EL DAREER SM, HILL DL: Disposition of 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-phosphate in mice and dogs. Cancer Treat. Rep. (1983) 67(5):445-456.
   Google Scholar
• AVRAMIS VI: Pharmacodynamics and proposed mechanism of therapeutic action and host toxicity of 9-β-d-arabinofuranosyl-2-fluoroadenine monophosphate (F-araAMP) in P388 murine leukemia-bearing mice. Cancer Invest. (1989) 7(2):129-137.
   PubMed Web of Science ®Google Scholar
• GREVER M, LEIBY J, KRAUT E et al.: A comprehensive Phase I and II clinical investigation of fludarabine phosphate. Semin. Oncol. (1990) 17(5 Suppl. 8):39-48.
   PubMedGoogle Scholar
• GREVER MR, KOPECKY KJ, COLTMAN CA et al.: Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. (1988) 30(5-6):457-459.
   Google Scholar
• HUTTON JJ, VON HOFF DD, KUHN J et al.: Phase I clinical investigation of 9-β-d-arabinofuranosyl-2-fluoroadenine 5′-monophosphate (NSC 312887), a new purine antimetabolite. Cancer Res. (1984) 44(9):4183-4186.
   PubMed Web of Science ®Google Scholar
• VON HOFF DD: Phase I clinical trials with fludarabine phosphate. Semin. Oncol. (1990) 17(5 Suppl. 8):33-38.
   Google Scholar
• MALSPEIS L, GREVER MR, STAUBUS AE, YOUNG D: Pharmacokinetics of 2-F-ara-A (9-β-d-arabinofuranosyl-2-fluoroadenine) in cancer patients during the Phase I clinical investigation of fludarabine phosphate. Semin. Oncol. (1990) 17(5 Suppl. 8):18-32.
   PubMed Web of Science ®Google Scholar
• GANDHI V, KEMENA A, KEATING MJ, PLUNKETT W: Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk. Lymphoma (1993) 10(1-2):49-56.
   Web of Science ®Google Scholar
• HERSH MR, KUHN JG, PHILLIPS JL et al.: Pharmacokinetic study of fludarabine phosphate (NSC 312887). Cancer Chemother. Pharmacol. (1986) 17(3):277-280.
   PubMed Web of Science ®Google Scholar
• LICHTMAN SM ETCUBANAS E, BUDMAN DR et al.: The pharmacokinetics and pharmacodynamics of fludarabine phosphate in patients with renal impairment: a prospective dose adjustment study. Cancer Invest. (2002) 20(7-8):904-913.
   PubMed Web of Science ®Google Scholar
• CHESON BD, VENA DA, FOSS FM, SORENSEN JM: Neurotoxicity of purine analogs: a review. J. Clin. Oncol. (1994) 12(10):2216-2228.
   PubMed Web of Science ®Google Scholar
• WARRELL RP Jr, BERMAN E: Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J. Clin. Oncol. (1986) 4(1):74-79.
   PubMed Web of Science ®Google Scholar
• SPRIGGS DR, STOPA E, MAYER RJ, SCHOENE W, KUFE DW: Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: Phase I and neuropathological study. Cancer Res. (1986) 46(11):5953-5958.
   PubMed Web of Science ®Google Scholar
• CATOVSKY D, RICHARDS S, HILLMEN P: Early results from LRF CLL4: a UK multicenter randomized trial. ASH Annual Meeting Abstracts (2005) 106(11):716.
   Google Scholar
• KEATING MJ, KANTARJIAN H, TALPAZ M, REDMAN J, MCCREDIE KB: Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv. Rev. Fr. Hematol. (1988) 30(5-6):461-466.
   Google Scholar
• KEATING MJ, KANTARJIAN H, TALPAZ M et al.: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood (1989) 74(1):19-25.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, KANTARJIAN H, O’BRIEN S et al.: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. (1991) 9(1):44-49.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O’BRIEN S, KANTARJIAN H et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 81(11):2878-2884.
   PubMed Web of Science ®Google Scholar
• FENCHEL K, BERGMANN L, WIJERMANS P et al.: Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk. Lymphoma (1995) 18(5-6):485-492.
   Google Scholar
• MONTILLO M, TEDESCHI A, DELFINI C et al.: Effectiveness of fludarabine in advanced B-cell chronic lymphocytic leukemia. Tumori (1995) 81(6):419-423.
   PubMed Web of Science ®Google Scholar
• MONTSERRAT E, LOPEZ-LORENZO JL, MANSO F et al.: Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk. Lymphoma (1996) 21(5-6):467-472.
   PubMed Web of Science ®Google Scholar
• SORENSEN JM, VENA DA, FALLAVOLLITA A, CHUN HG, CHESON BD: Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J. Clin. Oncol. (1997) 15(2):458-465.
   PubMed Web of Science ®Google Scholar
• RAI KR, PETERSON BL, APPELBAUM FR et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. (2000) 343(24):1750-1757.
   PubMed Web of Science ®Google Scholar
• JOHNSON S, SMITH AG, LOFFLER H et al.: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet (1996) 347(9013):1432-1438.
   PubMed Web of Science ®Google Scholar
• LEPORRIER M, CHEVRET S, CAZIN B et al.: Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood (2001) 98(8):2319-2325.
   PubMed Web of Science ®Google Scholar
• EICHHORST BF, BUSCH R, HOPFINGER G et al.: Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (Pts) with advanced chronic lymphocytic leukemia (CLL): results of a meta-analysis of two Phase III trials of the German CLL Study Group (GCLLSG). ASH Annual Meeting Abstracts (2005) 106(11):717.
   Google Scholar
• O’BRIEN S, KANTARJIAN H, BERAN M et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood (1993) 82(6):1695-1700.
   PubMed Web of Science ®Google Scholar
• KEATING MJ: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin. Oncol. (1990) 17(5 Suppl. 8):49-62.
   PubMed Web of Science ®Google Scholar
• WEISS M, SPIESS T, BERMAN E, KEMPIN S: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia (1994) 8(8):1290-1293.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O’BRIEN S, LERNER S et al.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood (1998) 92(4):1165-1171.
   PubMed Web of Science ®Google Scholar
• ROBERTSON LE, KEATING MJ: Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treat. Res. (1993) 64:105-119.
   PubMedGoogle Scholar
• ANAISSIE EJ, KONTOYIANNIS DP, O’BRIEN S et al.: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann. Intern. Med. (1998) 129(7):559-566.
   PubMed Web of Science ®Google Scholar
• WEISS MA, GLENN M, MASLAK P et al.: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia (2000) 14(9):1577-1582.
   PubMed Web of Science ®Google Scholar
• HALLEK M, SCHMITT B, WILHELM M et al.: Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a Phase II study of the German CLL Study Group. Br. J. Haematol. (2001) 114(2):342-348.
   PubMed Web of Science ®Google Scholar
• O’BRIEN SM, KANTARJIAN HM, CORTES J et al.: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. (2001) 19(5):1414-1420.
   PubMed Web of Science ®Google Scholar
• MAROTTA G, BIGAZZI C, LENOCI M et al.: Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica (2000) 85(12):1268-1270.
   PubMed Web of Science ®Google Scholar
• EICHHORST BF, BUSCH R, HOPFINGER G et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood (2006) 107(3):885-891.
   PubMed Web of Science ®Google Scholar
• OSCIER DG, RICHARDS S, ORCHARD J et al.: Prognostic factors in the UK LRF CLL4 trial. ASH Annual Meeting Abstracts (2005) 106(11):2099.
   Google Scholar
• SCHMITT B, WENDTNER CM, BERGMANN M et al.: Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia. Clin. Lymphoma (2002) 3(1):26-35.
   Google Scholar
• TSIMBERIDOU AM, KEATING MJ, GILES FJ et al.: Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer (2004) 100(12):2583-2591.
   PubMedGoogle Scholar
• GILES FJ, SHI GG, CORTES JE et al.: Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother. Pharmacol. (2003) 52(3):223-228.
   PubMedGoogle Scholar
• O’BRIEN S, KANTARJIAN H, BERAN M et al.: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia (1997) 11(10):1631-1635.
   PubMed Web of Science ®Google Scholar
• SUDHOFF T, ARNING M, SCHNEIDER W: Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Leukemia (1997) 11(Suppl. 2):S38-S41.
   Google Scholar
• SCHULZ H, KLEIN SK, REHWALD U et al.: Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood (2002) 100(9):3115-3120.
   PubMed Web of Science ®Google Scholar
• BYRD JC, PETERSON BL, MORRISON VA et al.: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood (2003) 101(1):6-14.
   PubMed Web of Science ®Google Scholar
• BYRD JC, RAI K, PETERSON BL et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood (2005) 105(1):49-53.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, O’BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4079-4088.
   PubMed Web of Science ®Google Scholar
• KEATING M, O’BRIEN S, ALBITAR M et al.: Extended follow-up of a chemo-immunotherapy regimen FCR (fludarabine, F; cyclophosphamide, C; and rituximab, R) as initial therapy for chronic lymphocytic leukemia (CLL). Blood (2005) 106. (Abstract 2118).
   Google Scholar
• WIERDA W, O’BRIEN S, WEN S et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol. (2005) 23(18):4070-4078.
   PubMed Web of Science ®Google Scholar
• WIERDA W, O’BRIEN S, FADERL S et al.: A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer (2006) 106(2):337-345.
   PubMed Web of Science ®Google Scholar
• KENNEDY B, RAWSTRON A, CARTER C et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99(6):2245-2247.
   PubMed Web of Science ®Google Scholar
• ELTER T, BORCHMANN P, SCHULZ H et al.: Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a Phase II trial. J. Clin. Oncol. (2005) 23(28):7024-7031.
   PubMed Web of Science ®Google Scholar
• SAYALA H, MORETON P, JONES RA et al.: Interim report of the UKCLL02 trial: a Phase II study of subcutaneous alemtuzumab plus fludarabine in patients with fludarabine-refractory CLL (on behalf of the NCRI CLL trials sub-group). Blood (2005) 106(11):23. (Abstract 2120).
   Google Scholar
• WENDTNER CM, RITGEN M, SCHWEIGHOFER CD et al.: Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter Phase III trial of the German CLL Study Group (GCLLSG). Leukemia (2004) 18(6):1093-1101.
   PubMed Web of Science ®Google Scholar
• O’BRIEN SM, KANTARJIAN HM, THOMAS DA et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer (2003) 98(12):2657-2663.
   PubMed Web of Science ®Google Scholar
• MONTILLO M, TEDESCHI A, MIQUELEIZ S et al.: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2006) 24(15):2337-2342.
   PubMed Web of Science ®Google Scholar
• PLOSKER GL, FIGGITT DP: Oral fludarabine. Drugs (2003) 63(21):2317-2323.
   PubMedGoogle Scholar
• FORAN JM, OSCIER D, ORCHARD J et al.: Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with ‘low-grade’ non-Hodgkin’s lymphoma and B-cell chronic lymphocytic leukemia. J. Clin. Oncol. (1999) 17(5):1574-1579.
   PubMed Web of Science ®Google Scholar
• MALSPEIS L, STAUBUS AE, LYON M, et al.: Oral bioavailability of 2-F-ara-A from fludarabine phosphate capsules in dogs. Proc. Am. Assoc. Cancer Res. (1989):30.
   Google Scholar
• BOOGAERTS MA: Oral fludarabine therapy in chronic lymphocytic leukemia-increased convenience. Hematol. J. (2004) 5(Suppl. 1):S31-S37.
   Google Scholar
• ROSSI JF, VAN HA, DE BK et al.: Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol. (2004) 22(7):1260-1267.
   PubMed Web of Science ®Google Scholar
• BOOGAERTS MA, VAN HA, CATOVSKY D et al.: Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. (2001) 19(22):4252-4258.
   PubMed Web of Science ®Google Scholar
• HILLMEN P, RICHARDS S, CATOVSKY D; UK NCRI CLL TRIALS GROUP: Comparison of oral and intravenous fludarabine in the LRF CLL4 trial. ASH Annual Meeting Abstracts (2005) 106(11):722.
   Google Scholar
• ALEXANDER RL, KUCERA GL: Lipid nucleoside conjugates for the treatment of cancer. Curr. Pharm. Des. (2005) 11(9):1079-1089.
   Google Scholar
• KEATING MJ, O’BRIEN S, KONTOYIANNIS D et al.: Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk. Lymphoma (2002) 43(9):1755-1762.
   Google Scholar
• PERKINS JG, FLYNN JM, HOWARD RS, BYRD JC: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer (2002) 94(7):2033-2039.
   PubMed Web of Science ®Google Scholar
• PFITZNER T, REISER M, BARTH S et al.: Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann. Hematol. (2002) 81(5):258-266.
   PubMed Web of Science ®Google Scholar
• PFITZNER T, ENGERT A, WITTOR H et al.: A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia. Leukemia (2000) 14(4):754-766.
   PubMed Web of Science ®Google Scholar
• DI RAIMONDO RF, GIUSTOLISI R, LERNER S et al.: Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann. Oncol. (2001) 12(5):621-625.
   PubMed Web of Science ®Google Scholar
• KEATING MJ, SMITH TL, LERNER S et al.: Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk. Lymphoma (2000) 37(1-2):71-85.
   Google Scholar
• DAMLE RN, WASIL T, FAIS F et al.: IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 94(6):1840-1847.
   PubMed Web of Science ®Google Scholar
• VASCONCELOS Y, DAVI F, LEVY V et al.: Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J. Clin. Oncol. (2003) 21(21):3928-3932.
   PubMed Web of Science ®Google Scholar